Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 14 11:11

Among 174 pharmaceutical items, selected for national Chinese Patent Medicine collection, the implementation will take place in April.

The National Chinese Patent Medicine Joint Procurement Office has announced the results of the third batch of national Chinese Patent Medicine procurement alliance collective selection, revealing that 174 pharmaceutical products were ultimately selected. The collective procurement under the National Chinese Patent Medicine Alliance involves 20 product groups and 95 products. After the announcement of results, regional alliances will be organized to implement the agreed procurement volume and sign purchase-sale contracts and other related work. The results of the national Chinese Patent Medicine alliance collective procurement are expected to be implemented nationwide in April. Among the top 50 Chinese Patent Medicine products ranked by provincial-level platforms, 34 are exclusive varieties. The large number of exclusive products and high concentration result in weak substitutability of collective procurement products of Chinese Patent Medicine, leading to insufficient price reduction motivation for enterprise

AASTOCKSFeb 12 10:41

SSY GROUP (02005) canceled 4.046 million shares that had been repurchased.

SSY GROUP (02005) announced that on February 5, 2025, the company will cancel 4.046 million shares that have been...

Zhitong FinanceFeb 5 17:52

China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong FinanceJan 21 07:54

SSY Group Gains Approval for Key Drug Developments

TipRanksJan 20 16:38

SSY GROUP (02005) obtained the pharmaceutical production registration certificate from the National Medical Products Administration for the composite potassium hydrogen phosphate injection (5ml).

SSY GROUP (02005) announced that the group has obtained approval from the National Medical Products Administration of China...

Zhitong FinanceJan 20 16:36